Appendix 1—figure 14. Serial donations of 218 convalescent plasma donors (symptomatic and known date of onset, PCR-positive) and 7675 repeat whole blood donors (unknown if symptomatic or date of onset, unknown PCR status) included in this study.

These cohorts were used to determine the rate of antibody waning and time-to-seroreversion distributions for the anti-nucleocapsid chemiluminescent microparticle immunoassays.